3-甲氧基苯肼盐酸 | 39232-91-2

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香醛(含缩醛,半缩醛)
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲氧基苯肼盐酸
• 中文别名: 3-甲氧基苯肼盐酸盐
• 英文名称: m-methoxyphenylhydrazine hydrochloride
• 英文别名: (3-methoxyphenyl)hydrazine hydrochloride；3-Methoxyphenylhydrazinehydrochloride；hydron;(3-methoxyphenyl)hydrazine;chloride
• CAS: 39232-91-2
• 化学式: C₇H₁₀N₂O*ClH
• mdl: MFCD00044416
• 分子量: 174.63
• InChiKey: GMXFZBZOVZOYNQ-UHFFFAOYSA-N

物化性质

• 熔点：
  142°C (dec.)
• 稳定性/保质期：

  常规情况下不会分解，也没有任何危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.21
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  47.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2928000090
• 危险品运输编号：
  2811
• 危险类别：
  6.1
• 包装等级：
  III
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  密封、阴凉、干燥保存

SDS

Name:	3-Methoxyphenylhydrazine hydrochloride 98% Material Safety Data Sheet
Synonym:	None
CAS:	39232-91-2

Section 1 - Chemical Product MSDS Name:3-Methoxyphenylhydrazine hydrochloride 98% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
39232-91-2	3-Methoxyphenylhydrazine hydrochloride	98	254-368-4

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation. Use with adequate ventilation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 39232-91-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin. Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: purple
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 142 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: > 142 deg C
Solubility in water: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C7H10N2O.HCl
Molecular Weight: 174.63

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 39232-91-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Methoxyphenylhydrazine hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 39232-91-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 39232-91-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 39232-91-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-甲氧基苯肼盐酸属于取代苯肼类有机物，广泛用作医药、农药和染料领域中非常重要的中间体。

制备

将0.50摩尔（65.6克）的3-甲氧基苯胺与213克416克18%盐酸溶液（2.0摩尔，213克）混合均匀，降温至0～-5℃。称取0.51摩尔（35克）亚硝酸钠并溶解于82克水中制备30%的水溶液，将此溶液缓慢滴加到上述体系中，1小时后检测无原料剩余，得到重氮盐体系。

将144克（0.87摩尔）亚硫酸钾溶于800克水中，并加入稀盐酸调节pH至6-8之间，降温至0℃。随后将重氮盐体系滴加到亚硫酸钾溶液中，同时滴加15%氢氧化钾水溶液以控制pH在6-8之间。滴加完成后，在0℃下保温1小时，然后将体系加热至60℃反应2小时，检测无重氮盐剩余。

向体系中加入200克（2摩尔，4等当量，36%）的盐酸，升温至100℃反应2小时。体系澄清后进行抽滤，滤液冷却析晶；将滤饼再次抽滤得到湿品130克，含量为63%，最终收率为93.8%。

反应信息

• 作为反应物：
  描述：

  3-甲氧基苯肼盐酸 在 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 生成 3-甲氧基-苯肼
  参考文献：
  名称：

  基于查尔酮的环丙基酮和肼之间的 Cloke-Wilson 型重排串联反应合成四氢哒嗪

  摘要：

  开发了一种以环丙基酮和肼为原料合成多取代四氢哒嗪的简便有效的方法。该转化基于查尔酮，通过 HFIP 中 TfOH 催化的 Cloke-Wilson 型重排串联反应发生。

  DOI：

  10.1021/acs.joc.3c02824
• 作为产物：
  描述：

  间氨基苯甲醚 在 盐酸 、 sodium nitrite 、 tin(ll) chloride 作用下， 以 水 为溶剂， 反应 1.5h， 生成 3-甲氧基苯肼盐酸
  参考文献：
  名称：

  发现了以FtsZ为目标的含1,3,4-恶二唑-2-酮的苯甲酰胺衍生物，可作为杀死多种MDR细菌菌株的高效药物。

  摘要：

  由耐多药（MDR）病原体（例如耐甲氧西林的金黄色葡萄球菌（MRSA）和耐万古霉素的金黄色葡萄球菌（VRSA））引起的感染扩散，引起了人们对具有新作用机制的新型抗生素的需求。细菌分裂蛋白FtsZ已被鉴定为可在临床上开发的新型药物靶标。作为开发靶向FtsZ的抗菌剂的持续努力的一部分，我们在此描述了六种系列的新型含1,3,4-恶二唑-2-one，1,2,4-三唑-的设计，合成和生物活性。含3-one和含吡唑啉-5-one的苯甲酰胺衍生物。其中，化合物A14被发现是最有效的抗菌剂，对所有测试的革兰氏阳性菌株均优于环丙沙星，利奈唑胺和红霉素等临床药物，特别是耐甲氧西林，耐青霉素和临床分离的金黄色葡萄球菌。随后的生物学活性和对接分析研究证明，A14可以作为靶向FtsZ的有效化合物。初步的SAR表明了进一步优化这些新颖类似物的总体方向。综上所述，这项研究为开发新型靶向FtsZ的杀菌剂提供了有希望的化学型。

  DOI：

  10.1016/j.bmc.2019.06.010
• 作为试剂：
  描述：

  (2S,4R)-1-(3-oxo-thiobutyryl)-4-(2-trifluoromethyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid methyl ester 、 (2R,4R)-1-(3-oxo-thiobutyryl)-4-(2-trifluoromethyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid methyl ester 、 3-甲氧基苯肼盐酸 、 (2R,4R)-1-[2-(3-methoxy-phenyl)-5-methyl-2H-pyrazol-3-yl]-4-(2-trifluoromethyl-benzenesulfonyl)-pyrrolidine-2-carboxylic acid methyl ester 在 3-甲氧基苯肼盐酸 作用下， 反应 192.0h， 生成 (2S,4R)-1-[2-(3-Methoxy-phenyl)-5-methyl-2H-pyrazol-3-yl]-4-(2-trifluoromethyl-benzenesulfonyl)-pyrrolidine-2-carboxylic Acid Methyl Ester
  参考文献：
  名称：

  Proline derivatives

  摘要：

  本发明涉及一种式为(I)的化合物，其中A，R1-R6在说明书和权利要求书中定义。式(I)化合物可用作药物。

  公开号：

  US08163793B2

文献信息

• N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase
  申请人：Merck Frosst Canada, Inc.

  公开号：US05604253A1

  公开（公告）日：1997-02-18

  The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  这项发明涵盖了式I的新化合物，以及一种治疗环氧合酶-2介导疾病的方法，包括向需要此类治疗的患者施用式I化合物的非毒性治疗有效量。 该发明还涵盖了用于治疗环氧合酶-2介导疾病的某些含有式I化合物的药物组合物。
• Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts
  申请人：SHANGHAI HYBRID-CHEM TECHNOLOGIES

  公开号：US20190152896A1

  公开（公告）日：2019-05-23

  The present invention provided a continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts. Diazotization, reduction, acidic hydrolysis and salifying with acids are innovatively integrated together. Using acidic liquids of aniline or substituted aniline, diazotization reagents, reductants and acids as raw materials, phenylhydrazine derivative salts is obtained through the synthesis process, which is a three-step continuous tandem reaction including diazotization, reduction, acidic hydrolysis and salifying. The described synthesis process is a kind of integrated solutions, which is carried out in an integrated reactor. The feed inlets of the integrated reactor are continuously filled with raw materials. In the integrated reactor, diazotization, reduction, acidic hydrolysis and salifying are carried out continuously and orderly, and phenylhydrazine salts or substituted phenylhydrazine salts is obtained in the outlet of the integrated reactor without interruption. The total reaction time is no more than 20 min.

  本发明提供了一种连续流程，用于合成苯肼盐和取代苯肼盐。重氮化、还原、酸性水解和酸化与酸类创新地集成在一起。使用苯胺或取代苯胺的酸性液体、重氮化试剂、还原剂和酸类作为原料，通过合成过程获得苯肼衍生物盐，这是一个包括重氮化、还原、酸性水解和酸化的三步连续串联反应。所述的合成过程是一种集成解决方案，是在一个集成反应器中进行的。集成反应器的进料口连续填充原料。在集成反应器中，重氮化、还原、酸性水解和酸化被连续有序地进行，苯肼盐或取代苯肼盐在集成反应器的出口处获得，没有中断。总反应时间不超过20分钟。
• Aerobic Oxidation of Alkyl 2-Phenylhydrazinecarboxylates Catalyzed by CuCl and DMAP
  作者：Min Hye Kim、Jinho Kim

  DOI：10.1021/acs.joc.7b03119

  日期：2018.2.2

  various fruitful organic reactions such as a catalytic Mitsunobu reaction were reported by virtue of alkyl 2-phenylazocarboxylates, however, the synthesis of alkyl 2-phenylazocarboxylates largely depended on the stoichiometric use of toxic oxidants. In this manuscript, an environment-friendly aerobic oxidative transformation of alkyl 2-phenylhydrazinecarboxylates to alkyl 2-phenylazocarboxylates is

  近来，由于2-苯基偶氮羧酸烷基酯，报道了各种富有成效的有机反应，例如催化的Mitsunobu反应，但是，2-苯基偶氮羧酸烷基酯的合成很大程度上取决于有毒氧化剂的化学计量使用。在该手稿中，公开了一种环境友好的2-苯基肼甲酸烷基酯的好氧氧化转化为2-苯基偶氮羧酸烷基酯的方法。在温和条件下，使用CuCl和DMAP系统可有效催化2-苯基肼甲酸烷基酯的需氧氧化。本发明的铜催化反应速率比以前报道的铁催化速率快得多，并且在3小时内合成了多种偶氮产物。本协议在更大范围内是有效的。
• [EN] DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS<br/>[FR] DIHYDROPYRIDAZINONES SUBSTITUÉES PAR DES PHÉNYLURÉES
  申请人：BAYER PHARMA AG

  公开号：WO2018086703A1

  公开（公告）日：2018-05-17

  Compounds of formula (I) which are nicotinamide phosphoribosyltransferase (NAMPT) inhibitors and their use for the treatment of hyperproloferative diseases and/or disorders responsive to induction of cell death.

  式（I）的化合物是烟酰胺磷酸核糖转移酶（NAMPT）抑制剂，可用于治疗对诱导细胞死亡敏感的增生性疾病和/或紊乱。
• [EN] PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE SOUS FORME DE PYRAZOLOPYRIMIDINES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004009602A1

  公开（公告）日：2004-01-29

  The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.

  本发明一般涉及激酶的抑制剂，更具体地涉及新型吡唑吡嘧啶化合物。

表征谱图